Calando Pharmaceuticals CEO James Hamilton has left the company, RNAi News has learned.
According to Calando CSO Thomas Schluep, Hamilton departed this summer. The CEO position has been filled by Christopher Anzalone, president and CEO of Calando’s parent firm Arrowhead Research.
Arrowhead also announced that Calando has named Mostafa Analoui and Bruce Given to its board of directors.
Analoui is currently head of healthcare and life science at the Livingston Group, a specialty investment firm, and senior vice president of business development at Charlesson Pharmaceuticals.
Given is currently the principal of Bruce Given Consulting, and previously served as president and CEO of Encysive Pharmaceuticals, which was acquired by Pfizer last year.
Rosetta Genomics said that it has named Kenneth Berlin as its new president and CEO.
Berlin replaces Amir Avniel, who announced in September that he would step down as Rosetta’s top official to become head of the company’s new plant biotechnology unit, Rosetta Green (see RNAi News, 9/10/2009).
Berlin previously served as worldwide general manager of Veridex, a Johnson & Johnson subsidiary focused on cellular and molecular cancer diagnostics. Before that, he was corporate counsel for Johnson & Johnson. He holds an AB from Princeton University and a JD from the University of California, Los Angeles, School of Law.